| Trial ID: | L4139 |
| Source ID: | NCT02501616
|
| Associated Drug: |
Metformin
|
| Title: |
Effect of Dapagliflozine on Systemic and Renal Endothelial Function
|
| Acronym: |
|
| Status: |
UNKNOWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Endothelial Function|Type 2 Diabetes
|
| Interventions: |
DRUG: Metformin|DRUG: Dapagliflozin
|
| Outcome Measures: |
Primary: Reactive hyperemic index to measure endothelial function, endothelial function, 8 weeks | Secondary: N-acetyl-β-D-glucosaminidase as a measure of renal tubular injury, renal tubular injury, 8 week|Urine albumin excretion ratio, Urine albumin excretion, 8 week|Urine β2 microglobulin, 8 week
|
| Sponsor/Collaborators: |
Sponsor: Seoul National University Hospital
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
22
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2014-12
|
| Completion Date: |
|
| Results First Posted: |
|
| Last Update Posted: |
2015-07-17
|
| Locations: |
Boramae medical center, Seoul, 156-707, Korea, Republic of
|
| URL: |
https://clinicaltrials.gov/show/NCT02501616
|
